Men's Health
PURLs
Can viscous fiber lower glycemic markers in type 2 diabetes?
The first meta-analysis to focus on viscous dietary fiber in T2D suggests a potential role for this supplement in improving glycemic control.
Applied Evidence
Atopic dermatitis: More than just a rash
Atopic dermatitis’ association with allergic rhinitis and asthma is well known, but there is also increased risk of food allergies, ADHD,...
Applied Evidence
Tactics to prevent or slow progression of CKD in patients with diabetes
Annual screening of urinary parameters, ongoing clinical vigilance, and proper medical therapy can help to keep declining renal function at bay....
From the Journals
PCPs play a small part in low-value care spending
Study indicates waste was widely distributed among specialties.
Applied Evidence
Breaking the cycle of medication overuse headache
Care of this disorder can be complex—from ruling out another secondary cause of headache to supervising detox from abortives, providing...
Applied Evidence
At-home exercises for 4 common musculoskeletal complaints
This pictorial review can help you advise patients on how to reduce pain and increase ROM, strength, and balance following acute injury or in...
Practice Alert
USPSTF update on sexually transmitted infections
Counseling—even if ≤ 30 minutes in a single session— can help curtail the spread of STIs, which are steadily increasing in incidence.
Applied Evidence
A new model of care to return holism to family medicine
Family medicine’s leadership in primary care is slipping as it loses its vision of whole-person care. This model of care can help us better manage...
Applied Evidence
Home visits: A practical approach
This service, which significantly improves outcomes for many patients, is beneficial in this time of COVID-19.
Commentary
Whole-person care: Our foundation, our future
We can no longer go “halfway” into whole-person care.
Clinical Inquiries
Does XR injectable naltrexone prevent relapse as effectively as daily sublingual buprenorphine-naloxone?
EVIDENCE-BASED ANSWER: Yes. Monthly extended-release injectable naltrexone (XR-NTX) treats opioid use disorder as effectively as daily sublingual...